The Window of Multiple Sclerosis

Size: px

Start display at page:

Download "The Window of Multiple Sclerosis"

서하 조
6 years ago
Views:

1 THE WINDOW OF MULTIPLE SCLEROSIS Vol.2 No.1 MAR 2009 Topic Review Article Review Case Review

2 The Window of Multiple Sclerosis

3 THE WINDOW OF MULTIPLE SCLEROSIS The Window of Multiple Sclerosis The Window of Multiple Sclerosis The Window of Multiple Sclerosis inquiry@kimsonline.co.kr Copyright 2009 All rights reserved. No part in this publication may be reproduced, stored in a system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without permission in written form from the publisher. This publication is published by MMK Co., Ltd., under continuing medical education granted from Merck Korea Limited. AP-MK-RB-09-01

4 The Window of Multiple Sclerosis Vol.2 No.1 MAR 2009

5 Topic Review CONTENTS Article Review Case Review

6 TOPIC R E V I E W World Congress on Treatment and Research in Multiple Sclerosis September 17-20, 2008 Montreal, Canada The Window of Multiple Sclerosis Vol.2 No.1 THE WINDOW OF MULTIPLE SCLEROSIS

7 THE WINDOW OF MULTIPLE SCLEROSIS Optic neuritis Transverse myelitis (typically longitudinally extensive) At least 2 of the following 3 supporting criteria: Brain MRI normal or showing nonspecific white matter lesions not meeting radiologic criteria for multiple sclerosis Spinal cord MRI showing lesion extending continuously over 3 or more vertebral segments (longitudinally extensive lesion) NMO-lgG seropositivity TOPIC REVIEW 6 7 Neuromyelitis optica Incomplete/partial forms of neuromyelitis optica Single or recurrent LETM Recurrent optic neuritis with negative brain MRI scan Asian optic-spinal multiple sclerosis Optic neuritis or LETM associated with coexisting systemic autoimmune disease Optic neuritis or LETM associated with distinct neuroimaging patterns such as hypothalamic lesions or periependymal brain lesions Vol.2 No.1

8 TOPIC R E V I E W THE WINDOW OF MULTIPLE SCLEROSIS Vol.2 No.1 A B THE WINDOW OF MULTIPLE SCLEROSIS

9 THE WINDOW OF MULTIPLE SCLEROSIS TOPIC REVIEW 8 9 Vol.2 No.1

1 13thAnnual meeting of the Americas committee for treatment and research in multiple scerosis 24th congress of the

10 TOPIC R E V I E W World Congress on Treatment and Research in Multiple Sclerosis September 17-20, 2008 Montreal, Canada The Window of Multiple Sclerosis Vol.2 No.1 13thAnnual meeting of the Americas committee for treatment and research in multiple scerosis 24th congress of the European committee for treatment and research in multiple scerosis 5th congress of the latin American committee for treatment and research in multiple scerosis THE WINDOW OF MULTIPLE SCLEROSIS

11 THE WINDOW OF MULTIPLE SCLEROSIS TOPIC REVIEW Vol.2 No.1

12 TOPIC R E V I E W THE WINDOW OF MULTIPLE SCLEROSIS Vol.2 No.1 THE WINDOW OF MULTIPLE SCLEROSIS

13 THE WINDOW OF MULTIPLE SCLEROSIS TOPIC REVIEW Vol.2 No.1

14 TOPIC R E V I E W THE WINDOW OF MULTIPLE SCLEROSIS Vol.2 No.1 THE WINDOW OF MULTIPLE SCLEROSIS

15 THE WINDOW OF MULTIPLE SCLEROSIS TOPIC REVIEW Vol.2 No.1

16 ARTICLE R E V I E W Defining the natural history 08 MS: the need for complete data and rigorous definitions Confavreux C. Mult Scler 2008;14: THE WINDOW OF MULTIPLE SCLEROSIS

17 THE WINDOW OF MULTIPLE SCLEROSIS 1. Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008;14: ARTICLE REVIEW Tremlett H, Zhao Y, Devonshire V. Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler 2008;14: ; author reply Vol.2 No.1

18 ARTICLE R E V I E W Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis Birnbaum G, Cree B, Altafullah I, et al. Neurology 2008;71: THE WINDOW OF MULTIPLE SCLEROSIS

19 THE WINDOW OF MULTIPLE SCLEROSIS ARTICLE REVIEW Vol.2 No.1

20 ARTICLE R E V I E W Kappos L, Gold R, Miller DH, et al. Lancet 2008;372: Efficacy and safety of oral fumarate in patients with relapsingremitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study THE WINDOW OF MULTIPLE SCLEROSIS

21 THE WINDOW OF MULTIPLE SCLEROSIS ARTICLE REVIEW Vol.2 No.1

22 ARTICLE R E V I E W Kopadze T, Kieseier BC, Dobert M, et al. Eur J Neurol 2009;16: Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis THE WINDOW OF MULTIPLE SCLEROSIS

23 THE WINDOW OF MULTIPLE SCLEROSIS ARTICLE REVIEW Vol.2 No.1

24 CASE R E V I E W Q1 A1 THE WINDOW OF MULTIPLE SCLEROSIS

25 THE WINDOW OF MULTIPLE SCLEROSIS REVIEW CASE Q2 Vol.2 No.1

26 CASE R E V I E W A2 THE WINDOW OF MULTIPLE SCLEROSIS

27 THE WINDOW OF MULTIPLE SCLEROSIS REVIEW CASE Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon b-1a subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352: Thompson, A.J., Benign multiple sclerosis, J Neurol Neurosurg Psychiatry 1999;67: Brex PA, Ciccare lli O, O Riordan Jl, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N E ngl J Med 2002;346: Gold R, Rieckmann P, chang P, Abdalla J; PRISMS Study Group. The long-term safety and tolerability of high-dose interferon b-1a in relapsing -remitting multiple sclerosis: 4-year data from the PRISMS study. European Journal of Neurology 2005;12: Vol.2 No.1

28 memo

30 The Window of Multiple Sclerosis The Window of Multiple Sclerosis THE WINDOW OF MULTIPLE SCLEROSIS QUIZ Vol.2 No.1 MAR 2009 Q1. Q2. Magnetic transfer imaging Diffusion tensor imaging Magnetic resonance spectroscopy The Window of Multiple Sclerosis The Window of MS Quiz Q1. Q2.

31 Balancing Performance & Safety

32 The Window of Multiple Sclerosis

인디쓔피-IOM핸돜벁닄큐1014pdf, page 59 @ Preflight ( IOM핸돜벁닄큐__1014 )

인디쓔피-IOM핸돜벁닄큐1014pdf, page 59 @ Preflight ( IOM핸돜벁닄큐__1014 ) Publisher: International Organization for Migration 17, route des Morillons 1211 Geneva 19 Switzerland Tel: +41.22.717 91 11 Fax: +41.22.798 61 50 E-mail: hq@iom.int Internet: http://www.iom.int ISBN 978